Sagimet Biosciences Inc. (NASDAQ:SGMT)
| Market Cap | $648.02M+36.1% |
| Revenue (ttm) | $0 |
| Net Income | -$53.32M+7.5% |
| EPS | -$1.19+33.1% |
| Shares Out | 71.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,501,037 |
| Open | $9.22 |
| Previous Close | $9.62 |
| Day's Range | $8.89 - $9.22 |
| 52-Week Range | $4.50 - $11.45 |
| Beta | 3.47 |
| Analysts | Buy |
| Price Target | $21.40(+135.68%) |
| Earnings Date | Mar 10, 2027 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating SGMT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 10, 2027Earnings report
$SGMT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SGMT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SGMT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SGMT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SGMT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SGMT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SGMT
| VTIVanguard Morningstar Total Stock Market ETF | $16.58M |
| IWMiShares Russell 2000 ETF | $14.45M |
| XBIState Street SPDR S&P Biotech ETF | $12.46M |
| VXFVanguard Extended Market ETF | $7.01M |
| IWOiShares Russell 2000 Growth ETF | $4.24M |
| IBBiShares Biotechnology ETF | $4.04M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SGMT’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.39% |
| ISMD | Inspire Small/Mid Cap ETF | 0.22% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.19% |
| IWC | iShares Micro-Cap ETF | 0.16% |
| BMED | iShares Health Innovation Active ETF | 0.14% |
| XBI | State Street SPDR S&P Biotech ETF | 0.14% |
| FTKI | First Trust Small Cap BuyWrite Income ETF | 0.07% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.04% |
| IBB | iShares Biotechnology ETF | 0.04% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.04% |
| IWO | iShares Russell 2000 Growth ETF | 0.04% |
| PWS | Pacer WealthShield ETF | 0.03% |
Weight is the stock’s share of each fund’s holdings.
